Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ Cdc42EP2 Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA531049
Description
Recommended positive controls: mouse heart. Predicted reactivity: Mouse (89%), Rat (87%), Rhesus Monkey (99%), Bovine (88%). Store product as a concentrated solution. Centrifuge briefly prior to opening the vial.
Cdc42, a small GTPase, regulates Actin polymerization, elongation of cell shape and cell signaling through interactions with many different downstream effector proteins, most of which contain a Cdc42-binding motif known as a CRIB domain. Cdc42EP2 (Cdc42 effector protein 2), also known as BORG1 or CEP2, is a 210 amino acid intracytoplasmic protein that localizes to both the cytoplasm and the cytoskeleton and contains one CRIB domain. Highly expressed in heart and present at lower levels in liver and pancreas, Cdc42EP2 interacts with Cdc42 and is thought to be involved in the organization of the Actin cytoskeleton and may also influence Actin filament assembly and overall cell shape.
Specifications
Cdc42EP2 | |
Polyclonal | |
Unconjugated | |
CDC42EP2 | |
1110008C05Rik; binder of Rho GTPases 1; Borg1; CDC42 effector protein (Rho GTPase binding) 2; CDC42 effector protein 2; CDC42EP2; CEP2; CRIB-containing BOGR1 protein; D19Bwg1013e | |
Rabbit | |
Antigen affinity chromatography | |
RUO | |
104252, 10435 | |
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles. | |
Liquid |
Western Blot | |
1 mg/mL | |
0.1M tris glycine with 20% glycerol and 0.01% thimerosal; pH 7 | |
O14613, Q8JZX9 | |
CDC42EP2 | |
Recombinant fragment corresponding to a region within amino acids 1 and 187 of Human CDC42EP2. | |
100 μL | |
Primary | |
Human, Mouse | |
Antibody | |
IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction